Form 4: Merus N.V. CFO Gregory D. Perry Granted Stock Options Following Shareholder Approval
SEC Form 4 Filing
Gregory D. Perry, CFO of Merus N.V., was granted options to purchase 107,300 common shares after the company's shareholders approved an increase in authorized share capital.
Summary
- Gregory D. Perry, the Chief Financial Officer of Merus N.V., was granted options to purchase 107,300 common shares.
- The grant was approved by the Board of Directors on February 1, 2024, subject to shareholder approval of an increase in authorized share capital.
- The Shareholder Approval Condition was met on May 7, 2024, when shareholders approved the amendment to the company's articles of association.
- The options have an exercise price of $36.09 per share.
- The options vest over a four-year period from January 1, 2024, with 25% vesting on January 1, 2025, and the remainder vesting in 36 equal monthly installments thereafter.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The shareholder approval is a positive sign.
Positives
- The grant of options aligns the CFO's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CFO.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives. This grant aligns with standard compensation practices.
Comparison to Industry Standards
- Stock option grants are a common component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen also utilize stock options to incentivize their executives.
- The size of the grant and the vesting schedule are generally in line with industry norms for companies of similar size and stage of development.
Stakeholder Impact
- Shareholders may view the option grant as a positive incentive for the CFO to drive company performance.
- Employees may see the grant as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 2024-02-01 | Board of Directors approved the grant of options, subject to Shareholder Approval Condition |
| 2024-01-01 | Vesting start date |
| 2024-05-07 | Shareholders approved the amendment to the Company's articles of association, satisfying the Shareholder Approval Condition |
| 2024-05-09 | Date of Form 4 filing |
| 2025-01-01 | First vesting date (25% of options) |
| 2034-01-31 | Expiration date of the options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.